Ulipristal Acetate

Ulipristal acetate (ellaOne®) is indicated for emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure. It is a selective progesterone receptor modulator, that works by preventing or delaying ovulation. ellaOne® works best if taken within 24 hours. By removing the need to obtain a prescription for this medicine, a faster women’s access to the medicine was enabled and therefore its effectiveness increased. Based on the assessment of available information, the CHMP found that ellaOne® can be used safely and effectively without medical prescription.

ellaOne® has been authorised in the EU since 2009 and extensive information on its risks and benefits has been collected and studied. Its safety profile is comparable to levonorgestrel-containing emergency contraceptives, which were already available without prescription in most EU countries and are registered for use up to 72 hours after unprotected intercourse or contraceptive failure.

Please report any case of pregnancy upon the use of ellaOne® using the following link:

Pregnancy Registry

This pregnancy registry is developed by HRA Pharma. It is aimed at collecting medical data about pregnancy outcomes in women exposed to ellaOne®.


back to the top